Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition

Checkpoint inhibitors have revolutionized cancer therapy and validated immunotherapy as an approach. Unfortunately, responses are seen in a minority of patients. Our objective is to use engineered adenoviruses designed to increase lymphocyte trafficking and cytokine production at the tumor, to asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Cervera-Carrascon, Victor, Quixabeira, Dafne C.A., Santos, Joao Manuel, Havunen, Riikka, Zafar, Sadia, Hemminki, Otto, Heiniö, Camilla, Munaro, Eleonora, Siurala, Mikko, Sorsa, Suvi, Mirtti, Tuomas, Järvinen, Petrus, Mildh, Markus, Nisen, Harry, Rannikko, Antti, Anttila, Marjukka, Kanerva, Anna, Hemminki, Akseli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458667/
https://www.ncbi.nlm.nih.gov/pubmed/32923123
http://dx.doi.org/10.1080/2162402X.2020.1761229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458667/
https://www.ncbi.nlm.nih.gov/pubmed/32923123
http://dx.doi.org/10.1080/2162402X.2020.1761229

Ejemplares similares